A press release from AbbVie states that clinical trials for the medication are presently in progress. According to the agreement, AbbVie will purchase Gilgamesh’s initiative to create this medication for $1.2 billion.
Gilgamesh will separate several other initiatives, including a medication for treating cardiovascular conditions, into a new organization – Gilgamesh Pharma Inc.
AbbVie stock declined by 1% during Monday’s trading session. Since the start of this year, their worth has risen by 17.4%ÑŽ
source: ft.com
